Abstract
Acquired QT syndrome is mainly caused by the administration of drugs that prolong ventricular repolarization. On the other hand, the risk of drug-induced torsades de pointes is increased by numerous predisposing factors, such as genetic predisposition, female sex, hypokalemia and cardiac dysfunction. This adverse reaction is induced by different chemical compounds used for the treatment of a variety of pathologies, including arrhythmias. As it is known, antiarrhythmic agents and other cardiovascular drugs can prolong the QT interval, causing this adverse reaction. Of the 20 most commonly reported drugs, 10 were cardiovascular agents and these appeared in 348 of the reports (46%). Class Ia antiarrhythmic agents have frequently been linked to inducing arrhythmia, including torsades de pointes. Sotalol and amiodarone, class III antiarrhythmics, are known to prolong the QT interval by blocking IKr. Due to the severity of events caused by the therapeutic use of these drugs, in this work of revision the cardiovascular drugs that present this property and the factors and evidence will be mentioned.
Keywords: QT interval, drug-induced torsades de pointes, antiarrhythmic drugs, amiodarone, sotalol, HERG channel
Current Drug Safety
Title: Cardiovascular Drugs Inducing QT Prolongation: Facts and Evidence
Volume: 5 Issue: 1
Author(s): Carlos A. Taira, Javier A.W. Opezzo, Marcos A. Mayer and Christian Hocht
Affiliation:
Keywords: QT interval, drug-induced torsades de pointes, antiarrhythmic drugs, amiodarone, sotalol, HERG channel
Abstract: Acquired QT syndrome is mainly caused by the administration of drugs that prolong ventricular repolarization. On the other hand, the risk of drug-induced torsades de pointes is increased by numerous predisposing factors, such as genetic predisposition, female sex, hypokalemia and cardiac dysfunction. This adverse reaction is induced by different chemical compounds used for the treatment of a variety of pathologies, including arrhythmias. As it is known, antiarrhythmic agents and other cardiovascular drugs can prolong the QT interval, causing this adverse reaction. Of the 20 most commonly reported drugs, 10 were cardiovascular agents and these appeared in 348 of the reports (46%). Class Ia antiarrhythmic agents have frequently been linked to inducing arrhythmia, including torsades de pointes. Sotalol and amiodarone, class III antiarrhythmics, are known to prolong the QT interval by blocking IKr. Due to the severity of events caused by the therapeutic use of these drugs, in this work of revision the cardiovascular drugs that present this property and the factors and evidence will be mentioned.
Export Options
About this article
Cite this article as:
Taira A. Carlos, Opezzo A.W. Javier, Mayer A. Marcos and Hocht Christian, Cardiovascular Drugs Inducing QT Prolongation: Facts and Evidence, Current Drug Safety 2010; 5 (1) . https://dx.doi.org/10.2174/157488610789869229
DOI https://dx.doi.org/10.2174/157488610789869229 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews New Electrocardiographic Features in Brugada Syndrome
Current Cardiology Reviews Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Limitations of Current Antiretroviral Agents and Opportunities for Development
Current Pharmaceutical Design Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
Current Neuropharmacology Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine The Role of Autophagy in the Gut Pathogens Clearance and Evasion
Current Protein & Peptide Science An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients
Current Vascular Pharmacology Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry